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ABSTRACT
Activation of the Hippo transducer TAZ is emerging as a novel oncogenic route in 
breast cancer and it has been associated with breast cancer stem cells. Additionally, 
TAZ expression has been linked with HER-2 positivity. We investigated the association 
between TAZ expression and pathological complete response in HER2-positive 
breast cancer patients treated with trastuzumab-based neoadjuvant therapy.TAZ 
was assessed in diagnostic core biopsies by immunohistochemistry. To categorize 
samples with low TAZ and samples with high TAZ we generated a score by combining 
staining intensity and cellular localization. The pathological complete response rate 
was 78.6% in patients with low TAZ tumors and 57.6% in patients with high TAZ 
tumors (p=0.082). In HER2-enriched tumors there was no significant association 
between TAZ and pathological complete response, whereas in the luminal B subtype 
the pathological complete response rate was 82.4% in tumors with low TAZ and 
44.4% in tumors with high TAZ (p=0.035). This association remained statistically 
significant when restricting our analysis to triple-positive tumors with expression of 
both estrogen receptor and progesterone receptor ≥ 50% (p=0.035). Results from 
this exploratory study suggest that the TAZ score efficiently predicts pathological 
complete response in Luminal B, HER2-positive breast cancer patients who received 
neoadjuvant chemotherapy and trastuzumab.
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INTRODUCTION
The Hippo pathway is an evolutionarily conserved 
regulator of tissue growth [1]. Mutations in Hippo 
pathway components give rise to tissue overgrowth in 
flies [2-3], and pathway defects have been associated with 
tumorigenesis in mice [4]. In human cancer mutations 
in core genes have rarely been detected in targeted and 
whole-genome sequencing studies [1]. Nevertheless, 
altered expression of different effectors has been found in a 
wide variety of tumors [5], thus suggesting that disruption 
of the Hippo signaling might result from the crosstalk with 
other perturbed molecular networks. The main function 
of Hippo pathway consists in negatively regulating two 
homologous oncoproteins: the transcriptional co-activator 
with PDZ-binding motif (TAZ) and Yes-associated protein 
(YAP). Attenuated Hippo signaling activates TAZ and 
YAP, which in turn feed a variety of tumor-promoting 
functions spanning from proliferation and cell survival 
to epithelial-mesenchymal transition and migration [1]. 
Moreover, Hippo-independent YAP/TAZ activation has 
been described [6]. 
In breast cancer (BC), TAZ has also been linked 
to cancer stem cells (CSCs) [7, 8], an uncommon 
subpopulation of cancer cells characterized by increased 
resistance to therapy-induced death stimuli [9]. Indeed, 
it has been demonstrated that TAZ sustains self-renewal 
and tumor-forming ability of breast CSCs [7]. We 
have recently strengthened this association by using 
molecularly characterized xenografts generated with 
patient-derived CSCs and their differentiated counterparts 
[8]. In an orthotopic mouse model we described the role 
of TAZ as a mediator of breast CSC metastatic ability and 
chemoresistance [8]. Moreover, in a preliminary analysis 
conducted in the clinical setting we found a statistically 
significant correlation between TAZ expression and 
shorter disease-free survival in a consecutive series of 
BC patients, and a positive correlation between TAZ and 
HER2 positivity [8]. 
The robustness of our preclinical findings, along 
with promising early clinical data, prompted this study 
to explore the association between TAZ, evaluated in 
diagnostic core biopsies, and pathological complete 
response (pCR) in HER2-positive BC patients treated with 
trastuzumab-based neoadjuvant therapy. 
RESULTS
Data on demographics, clinical features, 
therapy administered and treatment outcomes from 61 
HER2-positive BC patients treated with neoadjuvant 
trastuzumab-based therapy in three Italian Cancer Centers 
were retrieved from our prospectively maintained database 
and are illustrated in Table 1. 
To investigate the relationship between TAZ and 
pCR we generated a TAZ score that takes into account 
its activation status, as detailed in the methods section. 
We observed no association between standard clinical-
molecular factors and the TAZ score (Table 2), neither did 
Figure 1: Waterfall plot showing response data for luminal B patients. With + are indicated triple-positive tumors with high 
expression of hormonal receptors (≥ 50%) 
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we observe any relationship between standard clinical-
molecular factors and pCR (Table 3).
Overall, forty-one (67.2%) patients achieved a pCR 
(Table 4). In the whole cohort a pCR was recorded in 
78.6% of patients with low TAZ tumors and in 57.6% of 
patients with high TAZ tumors, even though this difference 
was not statistically significant (p=0.082) (Table 4). 
Neither the TAZ score nor the selected standard molecular-
clinical features showed evidence of a significant impact 
on pCR in the univariate and multivariate logistic 
regression models (Supplementary Table 1 and 2). 
When stratifying by molecular subtype, we did 
not observe any association between TAZ and pCR in 
HER2-enriched tumors (Table 4). In this subtype, the 
rate of pCRs was equal between cases with low TAZ 
and cases with high TAZ. Conversely, in the luminal B 
subtype the pCR rate was 82.4% in tumors with low TAZ 
and 44.4% in tumors with high TAZ (p=0.035) (Table 4). 
The association was confirmed by the regression model (≤ 
0.50 vs > 0.50 OR= 5.83; 95% CI, 1.23-27.63; p=0.026; 
supplementary Table 3). Finally, a statistically significant 
association was found in the subset of triple-positive 
tumors with high expression (≥ 50%) of both hormonal 
receptors (p=0.035) (Table 4). Individual responses in 
luminal B tumors are illustrated in figure 1. 
Table 1: Patients’ characteristics 
Characteristics N (%)
Age at biopsy 
Median (range)  48 (31-77)
Clinical stage 
   II




   Negative




   EC followed by DT




   Pre




   HER2-enriched
   Luminal B 
26 (42.6)
35 (57.4)
Abbreviations: E: epirubicin; C: cyclophosphamide; D: docetaxel; T: trastuzumab.









Overall population 28 (45.9) 33 (54.1)
Clinical stage
  II 9 (37.5) 15 (62.5) 0.289
  III 19 (51.4) 18 (48.6)
Nodal status
  Negative 6 (33.3) 12 (66.7) 0.202
  Positive 22 (51.2) 21 (48.8)
Neoadjuvant therapy
  EC followed by DT 20 (52.6) 18 (47.4) 0.175
  DT followed by ECT 8 (34.8) 15 (65.2)
Menopausal status
  Pre 14 (41.2) 20 (58.8) 0.406
  Post 14 (51.9) 13 (48.1)
Molecular subtype
  HER2-enriched 11 (42.3) 15 (57.7) 0.627
  Luminal B 17 (48.6) 18 (51.4)
Abbreviations: E: epirubicin; C: cyclophosphamide; D: docetaxel; T: trastuzumab. ■Chi2 test.
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DISCUSSION 
In this study we evaluated whether an association 
existed between TAZ and pCR in 61 HER2-positive BC 
patients who received neoadjuvant chemotherapy plus 
trastuzumab. To our knowledge, this is the first study 
investigating the predictive role of the Hippo transducer 
TAZ in this setting. No statistically significant association 
between TAZ and pCR was reported in the entire cohort. 
However, an association emerged when stratifying by 





Overall population 20 (32.8) 41 (67.2)
TAZ score
    ≤ 0.50
    > 0.50





HER2-enriched 7 (26.9) 19 (73.1)
TAZ score
    ≤ 0.50






Luminal B 13 (37.1) 22 (62.9)
TAZ score
    ≤ 0.50




  8  (44.4)
o0.03
TP50 6 (37.5) 10 (62.5)
TAZ score
    ≤ 0.50






Abbreviations: pCR: pathological complete response; TP50: triple-positive tumors with expression of estrogen receptor 
and progesterone receptor ≥ 50%. ■Chi2 test, oFisher Exact test.




Overall population 20 (32.8) 41 (67.2)
Clinical stage
II 6 (25.0) 18 (75.0) 0.297
III 14 (37.8) 23 (62.2)
Nodal status
Negative 7 (38.9) 11 (61.1) 0.511
Positive 13 (30.2) 30 (69.8)
Neoadjuvant therapy
EC followed by DT 11 (28.9) 27 (71.1) 0.412
DT followed by ECT 9 (39.1) 14 (60.9)
Menopausal status
Pre 11 (32.4) 23 (67.6) 0.935
Post 9 (33.3) 18 (66.7)
Molecular subtype
HER2-enriched 7 (26.9) 19 (73.1) 0.4
Luminal B 13 (37.1) 22 (62.9)
Abbreviations: pCR: pathological complete response; E: epirubicin; C: 
cyclophosphamide; D: docetaxel; T: trastuzumab. ■Chi2 test.
Table 3: Association between standard clinical-molecular factors and pCR 
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molecular subtype. While TAZ did not have any impact on 
pCR in HER2-enriched tumors, a significant association 
was observed in Luminal B tumors and in the subset with 
high expression of both hormonal receptors. As we did not 
note any association between standard clinical-molecular 
features and pCR, we provided hints supporting the 
hypothesis that TAZ is an independent predictive factor 
for pCR. Indeed, the inclusion of the proliferation marker 
Ki-67 in the models did not affect our study results (data 
available upon request). 
In interpreting our results, we are aware that 
this study is limited by its retrospective nature and 
the relatively restricted number of patients evaluated. 
Nevertheless, our study has some important strengths. 
First, the experimental path underlying this study 
deserves to be mentioned. Patient-derived xenografts 
generated with CSCs allow to reconstitute human tumors 
in the murine background and to amplify them through 
serial transplantation [10, 11]. As mentioned above, our 
interest on TAZ stemmed from molecularly characterized 
patient-derived xenografts obtained with the delivery of 
mammospheres, which are enriched for CSCs, generated 
from patients with Luminal B tumors [8]. Thus, our 
preclinical model may represent a promising tool for 
streamlining the preclinical-clinical transition of novel 
biomarkers. 
Second, over the past decade many prognostic and 
predictive multigene classifiers have been developed to 
assist in clinical decision-making [12]. Notwithstanding, 
even the broadest investigated genomic assays originally 
developed to foresee long-term outcomes are struggling 
to gain widespread consensus due to the unclear gain in 
precision and cost-effectiveness over standard prognostic 
factors [13]. We developed a clinically applicable assay 
with the potential to expand the current pipeline of 
biomarkers used in routine clinical practice. From a 
biological standpoint, it is worth mentioning that the TAZ 
score employed in this study was generated by considering 
cellular localization, and consequently TAZ activation. 
Indeed, cytoplasmic accumulation reflects ubiquitin-
mediated proteolysis, whereas nuclear translocation is 
usually interpreted as an activation of the TAZ-mediated 
oncogenic transcriptional program [14]. 
As pCR in an established surrogate marker for 
better long-term outcomes [15], it is of utmost importance 
to identify biomarkers of response and resistance to 
HER2-directed therapy. Even though a variety of putative 
predictive biomarkers have been proposed, spanning from 
gene expression profiles to mutations in HER2 and genes 
belonging to its transduction machinery [16-19], we are 
still waiting for validation studies. Even considering the 
sample size of our study, the magnitude of the difference 
in the pCR rate seen in Luminal B tumors according to 
TAZ status is rather uncommonly reported, and in our 
opinion represents a background for a prospective study 
with biomarker validation purposes. Moreover, the lesson 
we learned from clinical trials, such as NeoALTTO 
[20], GEPARQUINTO [21], and NeoSphere [22], is that 
hormone receptor-positive tumors achieve a lower rate of 
pCR compared with hormone receptor-negative tumors. 
Thus, foreseeing pCR after anti-HER2-based neoadjuvant 
therapy acquires an even more relevant therapeutic 
implication in this setting. With the present analysis we 
have provided clues on the potential predictive value of 
a TAZ-based biomarker in HER2-positive and hormone 
receptor-positive tumors. 
In summary, the message conveyed by this study 
is that the TAZ score we developed appears extremely 
promising in predicting the individual likelihood to 
achieve a pCR to trastuzumab-based neoadjuvant 
therapy in Luminal B, HER2-positive BC patients. As a 
consequence, we plan to prospectively validate the TAZ 
score as a molecular predictor in this BC subtype. Finally, 
our goal is to examine core components of the Hippo 
pathway in different therapeutic settings and molecular 
subtypes with the aim of identifying Hippo pathway-
related prognostic and predictive biomarkers. 
METHODS 
Study Participants and procedures 
Included patients were 61 HER2-positive BC 
patients who received neoadjuvant trastuzumab-based 
therapy. Patients were considered suitable for inclusion 
if they had received trastuzumab as a part of their 
neoadjuvant treatment, had complete data on baseline 
clinical features, therapy administered and treatment 
outcomes, if the planned treatment was completed, and 
the amount of biological materials was sufficient for 
TAZ analysis in their biopsies. Patients were treated 
with two different schedules: epirubicin 120 mg/m2 plus 
cyclophosphamide 600 mg/m2 administered intravenously 
(IV) on day 1 every 21 days for four cycles followed by 
docetaxel 100 mg/m2 plus trastuzumab 6 mg/kg (after a 
loading dose of 8 mg/kg) administered IV on day 1 every 
3 weeks for four cycles, or a reverse sequence with the 
administration of trastuzumab for the whole length of 
chemotherapy. pCR was defined as no residual invasive 
tumor in both breast and axilla (ypT0/is ypN0), and was 
assessed by local pathologists. The immunohistochemical 
assessment of estrogen receptor (ER), progesterone 
receptor (PgR) and HER2 was performed in formalin-
fixed paraffin-embedded tissues using the monoclonal 
antibodies (MoAbs) 6F11, 1A6 (Menarini, Florence, Italy) 
and the polyclonal antibody A0485 (PoAb, Dako, Milan, 
Italy). TAZ was evaluated with the MoAb anti-TAZ (M2-
616, BD Pharmingen, San Jose, CA,USA). ER and PgR 
were considered positive when ≥1% of the neoplastic 
cells showed a distinct nuclear immunoreactivity. 
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HER2 positivity was defined, according to ASCO-CAP 
guidelines, as 3+ overexpression by immunohistochemical 
testing or as 2+ with HER2 amplification by silver in situ 
hybridization (SISH, Inform HER2 DNA Probe; Inform 
Chr17 probe, Roche Diagnostics, Milan, Italy) [23]. TAZ 
was evaluated in diagnostic core biopsies and considered 
positive when >10% of tumor cells displayed nuclear and/
or cytoplasmic immunostaining. TAZ staining intensity 
was graded on a four-grade scale (0: negative, 1+: weak, 
2+: moderate, 3+: strong). The TAZ score was obtained 
by multiplying the staining intensity x 1.5 (nuclear 
localization) or 0.5 (cytoplasmic localization), in order to 
take into account its activation status. Using the median 
score of all tumors as a cut-off point, tumors with a score 
≤0.5 were considered as TAZ low, whereas tumors with a 
score >0.5 as TAZ high. TAZ expression and localization 
were independently evaluated by two investigators (MM 
and ADB) who were masked to treatment outcome. 
Discordant cases were reviewed at a face-to-face meeting. 
Statistical analysis 
We computed descriptive statistics for all variables 
of interest. Continuous data were reported as mean and 
standard deviation and we represented categorical data 
with frequencies and percentage values. In order to assess 
the relationships between categorical variables, different 
tests were employed: the Pearson’s Chi-squared test of 
independence (2-tailed) and the Fisher Exact test. We used 
a univariate logistic regression model to identify variables 
that could influence the study outcome (pCR). We planned 
to insert variables significant in the univariate analysis in a 
multivariate logistic regression. We considered statistically 
significant p values less than 0.05. Statistical analyses 
were carried out using SPSS software (SPSS version 21, 
SPSS Inc., Chicago, IL, USA). 
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